Search
NRX Pharmaceuticals Inc
NRXPAdd to Watchlist
3.280USD
+0.070+2.18%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
108.46MMarket Cap
LossP/E TTM
More Details of NRX Pharmaceuticals Inc Company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
NRX Pharmaceuticals Inc Info
Ticker SymbolNRXP
Company nameNRX Pharmaceuticals Inc
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 20
Address1201 Orange Street
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone14842546134
Websitehttps://www.nrxpharma.com/
Ticker SymbolNRXP
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Company Executives of NRX Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Anson Funds Management LP.
9.21%
B Group, Inc.
9.07%
Javitt (Jonathan C)
4.59%
Vanguard Capital Management, LLC
3.51%
Glytech LLC
2.91%
Other
70.71%
Shareholders
Shareholders
Proportion
Anson Funds Management LP.
9.21%
B Group, Inc.
9.07%
Javitt (Jonathan C)
4.59%
Vanguard Capital Management, LLC
3.51%
Glytech LLC
2.91%
Other
70.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.89%
Hedge Fund
9.31%
Individual Investor
5.39%
Corporation
2.91%
Investment Advisor/Hedge Fund
1.03%
Research Firm
0.14%
Bank and Trust
0.08%
Other
64.26%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
74
9.80M
29.64%
+5.09M
2025Q4
67
7.14M
25.42%
+3.67M
2025Q3
66
6.31M
26.53%
+3.75M
2025Q2
66
5.07M
29.31%
+1.44M
2025Q1
66
4.06M
26.08%
+505.82K
2024Q4
70
3.94M
22.32%
-356.61K
2024Q3
83
3.57M
28.23%
-628.46K
2024Q2
86
3.38M
32.03%
-634.67K
2024Q1
92
3.27M
34.30%
-835.14K
2023Q4
98
3.31M
81.28%
-805.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Anson Funds Management LP.
3.04M
9.21%
+1.02M
+50.31%
Dec 31, 2025
B Group, Inc.
3.00M
9.07%
+3.00M
--
Aug 18, 2025
Javitt (Jonathan C)
1.52M
4.59%
--
--
Feb 12, 2026
Glytech LLC
963.48K
2.91%
--
--
Feb 12, 2026
AdvisorShares Investments, LLC
328.00K
0.99%
-14.13K
-4.13%
Dec 31, 2025
Commonwealth Financial Network
366.63K
1.11%
+366.63K
--
Dec 31, 2025
Hurvitz (Chaim)
221.48K
0.67%
--
--
Feb 12, 2026
Geode Capital Management, L.L.C.
218.87K
0.66%
+33.00K
+17.76%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
6.62%
iShares Micro-Cap ETF
0.01%
AdvisorShares Psychedelics ETF
Proportion6.62%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
